PEG-MGF.
PEG-MGF is a PEGylated synthetic peptide based on the unique C-terminal E-domain of mechano growth factor (MGF), an alternatively spliced isoform of insulin-like growth factor-1 known as IGF-1Ec (the rodent equivalent is IGF-1Eb).
PEG-MGF is a PEGylated synthetic peptide based on the unique C-terminal E-domain of mechano growth factor (MGF), an alternatively spliced isoform of insulin-like growth factor-1 known as IGF-1Ec (the rodent equivalent is IGF-1Eb). PEG-MGF is research / preclinical, and PepCue grades its published evidence F tier (12/100). This is a research reference, not medical or dosing advice.
What it is
PEG-MGF is a PEGylated synthetic peptide based on the unique C-terminal E-domain of mechano growth factor (MGF), an alternatively spliced isoform of insulin-like growth factor-1 known as IGF-1Ec (the rodent equivalent is IGF-1Eb). MGF is produced locally by skeletal muscle in response to mechanical loading or damage; the research peptide reproduces its distinctive 24-amino-acid E-peptide rather than the full IGF-1 molecule. The polyethylene glycol (PEG) moiety is a chemical modification intended to slow degradation of the otherwise very short-lived native peptide. It is a research-use-only chemical, not an approved drug.
How it works
Native MGF arises when the IGF-1 gene is alternatively spliced after mechanical stress, producing a transcript whose distinct C-terminal "E-domain" differs from the IGF-1Ea isoform. The Goldspink group's central proposal, supported by cell-culture work, is that the MGF E-peptide acts to expand the pool of muscle satellite (stem) cells by promoting myoblast proliferation while delaying their differentiation, whereas mature IGF-1 drives differentiation and protein synthesis through the IGF-1 receptor (Yang & Goldspink, FEBS Lett 2002). Notably, several studies report that the isolated E-domain peptide exerts effects that do not appear to require classical IGF-1 receptor binding, implying a separate, still incompletely defined receptor/signaling pathway. PEGylation is intended only to lengthen circulating half-life and does not change this proposed biology.
Mechanism pathways
Downstream growth signalling through the IGF-1 receptor and its splice variants.
Insulin-like growth factor 1 is the main mediator of growth hormone's anabolic effects. Growth hormone binds its own receptor on hepatocytes, which dimerises and signals through the JAK2 and STAT5 pathway to drive IGF-1 transcription. Circulating IGF-1 then binds the IGF-1 receptor, a receptor tyrosine kinase closely related to the insulin receptor, which activates the PI3K, Akt, and mTOR cascade alongside the Ras and MAPK cascade. The result is increased protein synthesis, cell proliferation, and suppression of programmed cell death. Muscle also produces IGF-1 locally in response to mechanical loading, and this local supply is thought to matter more for tissue repair than the circulating pool does. A critical regulatory layer is the family of six IGF-binding proteins. The great majority of circulating IGF-1 is bound to these proteins rather than free, which limits how much reaches receptors at any moment and prevents excessive signalling. Several compounds in this group are engineered specifically to evade that control, using amino-acid substitutions and terminal extensions that drop binding-protein affinity dramatically. The consequence is a much larger free fraction and a far longer functional presence than native IGF-1, which is the intended effect and also the source of the main concern about them. A separate branch involves splice variants. Mechanical stress shifts IGF-1 splicing to produce a variant with a distinct carboxy-terminal E-domain, and the isolated E-peptide has been proposed to act on muscle satellite cells through a receptor different from the classical IGF-1 receptor, expanding the stem cell pool before mature IGF-1 drives differentiation. Attaching polyethylene glycol to this peptide is a stability modification rather than a change in mechanism. The honest position differs sharply between branches. Growth hormone and IGF-1 receptor biology is textbook physiology, well established in humans, and recombinant growth hormone is an approved medicine for defined deficiency states. The splice-variant branch is far weaker: independent laboratories have not consistently reproduced the proposed proliferative effect of the isolated E-peptide, and there are essentially no controlled human trials of it. Across the whole pathway, unregulated amplification of a proliferative growth signal raises theoretical concerns about promoting the growth of existing abnormal cells, and these compounds other than approved growth hormone have no established human safety record.
The evidence
The human evidence base for PEG-MGF specifically is essentially absent: no completed human clinical trials evaluating the PEGylated peptide for any indication could be identified. The underlying MGF biology rests on preclinical and ex vivo work, much of it from Geoffrey Goldspink's UCL group: mechanical stretch and stimulation induce an IGF-1 splice variant in rabbit and rodent muscle (Yang et al., J Physiol 1999; Hill & Goldspink, J Physiol 2003), the MGF E-peptide and mature IGF-1 play distinct proliferation-vs-differentiation roles in cultured myoblasts (Yang & Goldspink, FEBS Lett 2002), and a synthetic MGF E-peptide can act through a mechanism distinct from the IGF-1 receptor (Mills et al., 2007) and improve myogenic precursor cell transplantation in animals (Am J Transplant 2007). Animal studies have also explored MGF in acute myocardial infarction (Carpenter et al., Heart Lung Circ 2008) and neuronal injury models. These data establish biological plausibility for muscle repair signaling but do not demonstrate safety or efficacy of PEG-MGF in humans, and findings in cell/animal systems frequently fail to translate.
The evidence, in brief
A PEGylated synthetic mechano growth factor (an IGF-1 splice variant) implicated in satellite-cell activation and muscle repair. Evidence is essentially preclinical: cell and animal studies only. There are no human trials of PEG-MGF and no clinical safety data. Unapproved research compound.
- GH stimulates mechano growth factor expression and activates myoblast transformation in C2C12 cellsKobe J Med Sci, 2008 (PMID 18772608)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #049
Little indexed evidence or largely speculative.
Mostly online reports, no real study base yet.
Claim receipts
Popular claims about PEG-MGF, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Satellite-cell signaling is supported by cell and animal work; human muscle outcomes are untested.
No completed human clinical trial has evaluated the PEGylated peptide for any indication.
Recovery outcomes in people have not been measured in any controlled study.
No toxicology or clinical evaluation exists, and PEGylated therapeutics raise anti-PEG antibody questions unstudied here.
Safety profile
There is no human safety data for PEG-MGF; it has not undergone formal toxicology or clinical evaluation, so its adverse-effect profile, immunogenicity, and long-term risks in people are unknown. As a peptide in the IGF-1 family that promotes cell proliferation, a theoretical concern is unwanted stimulation of growth in non-target or abnormal tissues, though this has not been characterized for this molecule. PEGylated therapeutics as a class can elicit anti-PEG antibodies and, rarely, injection-site or hypersensitivity reactions, but whether this applies to PEG-MGF is unstudied. Research-grade material also carries quality, purity, and contamination uncertainties because it is not manufactured to pharmaceutical standards.
Compound notes
- PEG-MGF is a PEGylated form of Mechano Growth Factor (MGF), a splice variant of IGF-1 produced in response to muscle damage.
- PEGylation extends its half-life; it is studied for muscle repair and satellite-cell activation, largely preclinically.
- Not FDA-approved; research-only and prohibited in sport under WADA.
- Human efficacy and long-term safety are not established.
Regulatory status
PEG-MGF is not approved by the FDA or any major regulatory agency for any use and is sold only as a research-use-only chemical, not for human consumption. The mechano growth factor E-domain peptide is prohibited in sport: WADA lists growth factors affecting muscle, including MGF, under category S2 (peptide hormones, growth factors, related substances).
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01MGF is the IGF-1Ec splice variant of the IGF-1 gene, induced locally in muscle by mechanical loading or damage, not a separate gene
- 02The defining feature is its unique C-terminal E-domain peptide (~24 amino acids), which is the part PEG-MGF is built around
- 03Goldspink and colleagues at UCL coined the name 'mechano growth factor' in the late 1990s based on its mechanical-stress-dependent expression
- 04Proposed mechanism: the E-peptide expands the satellite (muscle stem) cell pool by promoting proliferation and delaying differentiation, distinct from mature IGF-1
- 05Multiple studies suggest the E-peptide acts via a pathway not dependent on the classical IGF-1 receptor
- 06No human clinical trials of PEG-MGF have been completed; the evidence is preclinical/ex vivo, and it is banned in sport under WADA category S2
PEG-MGF: research formats
Choose the format you are researching to see route-specific notes.
Sold as a lyophilized research vial. No human trials have been completed, so no format is validated in people.
PEG-MGF is the MGF E-domain peptide with a polyethylene glycol group attached to slow degradation of the otherwise very short-lived native peptide. It is sold as a research-use-only lyophilized vial, commonly 2 mg, and reconstituted with bacteriostatic water like other lyophilized peptides. Reconstituting 2 mg with 2.0 mL BAC water gives 1,000 mcg/mL.
The concentration math above is arithmetic, not evidence. No human clinical trials of PEG-MGF have been completed; the evidence base is preclinical and ex vivo, and the underlying E-peptide activity is itself contested.
PEG-MGF is not approved by any regulator and is prohibited in sport under WADA category S2 (peptide hormones, growth factors, and related substances).
Sources
Every factual claim above resolves to a real, published source.
- Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiationFEBS Letters, 2002, PMID 12095637
- Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damageThe Journal of Physiology, 2003, PMID 12692175
- A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation successAmerican Journal of Transplantation, 2007, PMID 17845560
- Mechano-growth factor reduces loss of cardiac function in acute myocardial infarctionHeart, Lung & Circulation, 2008, PMID 17581790
Cite this page
PepCue. “PEG-MGF: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/peg-mgf.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.